Jasmine Cui, InnoCare CEO
August 17, 2021 07:21 AM EDTUpdated August 18, 11:45 AM
Deals
China

In­no­Care bags Chi­nese rights to In­cyte CAR-T ri­val Mon­ju­vi in bid to ex­pand in-house pipeline

Jason Mast

Editor

Mer­ck vet­er­an Jas­mine Cui has turned Bei­jing-based In­no­Care in­to a $4 bil­lion com­pa­ny large­ly on the strength of a sin­gle BTK in­hibitor and a clutch …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times